| 20.48 Data as of May 24 |  -0.41 / -1.96%Today’s Change | 13.00 Today|||52-Week Range 21.29 | +30.03% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $1.5B |
Company Description
Wuxi PharmaTech (Cayman), Inc. provides research and development outsourcing services for the pharmaceutical, biotechnology, and medical device industries. It operates through the Laboratory Services and Manufacturing Services segments. The Laboratory Services segment offers a broad range pharmaceutical and biotech services including discovery and medicinal chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation and toxicology laboratory services, as well as testing services for biologics, medical devices and combination products. The Manufacturing Services segment involves the production of intermediates and active pharmaceutical ingredients for small-molecule pharmaceuticals used in preclinical and clinical testing. The company was founded by Li Ge, Liu Xiao Zhong, Zhang Zhao Hui, and Zhao Ning in 2000 and is headquartered in Shanghai, China.
Employees
Shareholders
| Other institutional | 46.53% |
| Mutual fund holders | 43.87% |
| Individual stakeholders | -- |
Top Executives
| Ge Li, PhD | Chairman & Chief Executive Officer |
| Edward Hu, MBA | Chief Operating & Financial Officer |
| Shu Hui Chen, PhD | Chief Scientific Officer |
| Xiao Zhong Liu | Director & Executive Vice President |
| Trabue D. Bryans | Vice President & GM-Atlanta Operations |
.
